Deutsche Bank Reiterates €120.00 Price Target for Bayer (BAYN)
Deutsche Bank set a €120.00 ($148.15) price objective on Bayer (FRA:BAYN) in a research note issued to investors on Thursday morning. The brokerage currently has a buy rating on the healthcare company’s stock.
Several other research analysts have also recently issued reports on BAYN. Sanford C. Bernstein set a €131.00 ($161.73) price target on shares of Bayer and gave the stock a buy rating in a report on Wednesday, November 29th. DZ Bank reissued a buy rating on shares of Bayer in a report on Monday, December 11th. UBS Group set a €125.00 ($154.32) price target on shares of Bayer and gave the stock a buy rating in a report on Monday, February 12th. Warburg Research set a €121.00 ($149.38) price target on shares of Bayer and gave the stock a neutral rating in a report on Wednesday, February 28th. Finally, Barclays set a €100.00 ($123.46) price target on shares of Bayer and gave the stock a sell rating in a report on Wednesday, January 3rd. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have given a buy rating to the stock. The company currently has a consensus rating of Buy and a consensus price target of €119.64 ($147.70).
Shares of Bayer (BAYN) opened at €92.27 ($113.91) on Thursday. Bayer has a 1-year low of €91.58 ($113.06) and a 1-year high of €123.82 ($152.86). The company has a market cap of $75,580.00 and a PE ratio of 24.80.
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.